Category: Press Release

Don Deyo, CEO, will be presenting on the status and direction for the Company at the Medical Alley Innovation Summit sponsored in conjunction with The MedTech Strategist. The conference brings the proven format of annual Dublin Innovation Summit to the epicenter of medtech innovation, Minneapolis-St. Paul, MN. The Company is honored to have the opportunity […]

The US Patent Office has granted the fifth FemPulse patent (#9,737,707). This new patent covers use of capacitor technology for both vaginally inserted and implantable nerve stimulation. The company’s IP portfolio continues to grow, with numerous additional claims filed.

The 15-subject enrollment level approved for the company-sponsored clinical study has been met. The final subject is expected to complete the multi-day protocol in approximately six weeks. The enrollment limit was reached in just 9 weeks, providing another indication of the tremendous number of women afflicted with OAB and the urgent need for new and […]

The Company is pleased to announce the first enrollment in its clinical evaluation to assess fit, comfort, patient placement and safety of the FemPulse therapy, as well as the potential for improvement in symptoms associated with OAB. The subject, a 69 year old female, was afflicted with urgency and urinary urge incontinence.

FemPulse LLC announces the formation of a formal board of directors (BoD) to help guide the strategic direction for the fast-moving organization. Members of the BoD includes the co-founders, Alexandra Haessler, MD and Peter Fredericks, MBA/PhD and Donald Deyo, Jeff Korn, Darrin Uecker and Flip Gianos. Don and Jeff serve as CEO and Corporate Counsel […]

Metro Urology, St. Paul, MN has received institutional review board approval to become the second center in the clinical study sponsored by the Company. Approval of Metro Urology by the Western IRB (WIRB) allows for the evaluation of this novel therapy in private practice, as well as in the previously approved academic institution. The Company […]

The Company announced today approval of the First-in-Human (FIH) clinical study of its novel, wearable neuromodulation platform for treating overactive bladder (OAB) in females. The Western IRB (WIRB) approved participation of up to 15 subjects in a study assessing fit, patient placement and safety of the FemPulse device, as well as potential for improvement in […]

The US Patent Office has granted the fourth FemPulse patent (#9,381,351). This broad patent grants claims regarding implantation and stimulation of nerves within the peritoneal cavity. With its extensive patent portfolio, FemPulse is uniquely positioned to advance the field of wearable neuromodulation therapy for Overactive Bladder.

Dr. Haessler was invited to present a talk titled, Neuroanatomy of Micturition, at the Neuromodulation: The Science conference. She shared the panel with international thought leaders Drs. de Groat, Grill and Hassouna. In her talk, Dr. Haessler addressed the neuroanatomy and neurophysiology of micturition, and potential mechanisms for neuromodulatory OAB therapy.

The journal, Start Up, featured an interview with Dr. Haessler highlighting her inspiration for the FemPulse system and motivation to create the company. The article, titled “FemPulse Pioneers on Multiple Fronts”, highlighted that a female device entrepreneur in Silicon Valley is rare. Dr. Haessler emphasized the importance of her connection with and compassion for her […]